New GLP1 Receptor fluorescent probes LUXendins developed by our collaborators Johannes Broichhagen and David J. Hodson

The glucagon-like peptide-1 receptor (GLP1R), expressed in peripheral tissues and brain, is known to be involved in several metabolic and inflammatory processes. Despite its clear interest from the therapeutic perspective, detection and visualization of GLP1R remains challenging, partly due to a lack of validated reagents.

Drs. Johannes Broichhagen -from the Max Planck Institute for Medical Research at Heidelberg and Leibniz-Forschungsinstitut fur Molekulare Pharmakologie, Berlin- and David J. Hodson – from the Institute of Metabolism and Systems Research (IMSR), and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham- have previously generated LUXendins, antagonistic red and far-red fluorescent probes for specific labeling of GLP1R in live and fixed cells/tissues.  

Now they have extended this concept to the green and near-infrared color ranges by synthesizing and testing novel LUXendins, among them LUXendin551 and LUXendin762.   

LUXendin551 acts as a chemical beta cell reporter in preclinical rodent models, while LUXendin762 allows noninvasive imaging, highlighting differentially accessible GLP1R populations. Both LUXendin551 and LUXendin762 are part of Celtarys Research portfolio of fluorescent probes.

Related posts

PROTAC hook effect
11 August 2026

PROTAC Hook Effect: How E3 Ligase and Target Protein Binding Affinity Shapes Degradation Efficiency

The PROTAC hook effect limits degrader potency at high concentrations. See how E3 ligase and target protein binding affinities shape degradation outcomes.
Read more
VHL, CRBN and Emerging Ligases like DCAF
8 July 2026

VHL, CRBN, and Emerging Ligases like DCAF: Selecting E3 Ligase Handles for PROTAC Drug Discovery

VHL, CRBN and emerging E3 ligases like DCAF: compare handles for your PROTAC program and run fluorescence-based binding assays with ready-to-use kits.
Read more
Fluorescence Polarization Binding Assays for E3 Ligases in Targeted Protein Degradation (TPD) Programs
25 May 2026

Fluorescence Polarization Binding Assays for E3 Ligases in Targeted Protein Degradation (TPD) Programs

Targeted protein degradation (TPD) has reshaped drug discovery by eliminating disease-driving proteins through the cell’s own degradation systems, rather than merely blocking their activity.
Read more
Buy now
0